Abstracts tagged "economics and rheumatoid arthritis (RA)"

Abstract Number: 2185 • 2018 ACR/ARHP Annual Meeting
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Andrew Hresko¹, Zhi Zhang², Joshua Colls², Michael E Weinblatt², Nancy A. Shadick² and Daniel Solomon², ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) affects over 1 million Medicare enrollees. Despite the size of this population, costs for RA within Medicare remain poorly understood, especially…
Abstract Number: 1044 • 2017 ACR/ARHP Annual Meeting
Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Andrew Hresko¹, Tzu-Chieh Lin² and Daniel H. Solomon³, ¹Tufts Medical School, Boston, MA, ²Health Outcomes, Amgen, Thousand Oaks, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last two decades…
Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Celine J. van de Laar¹, Laura M.M. Steunebrink², Martijn A.H. Oude Voshaar³ and Harald E. Vonkeman⁴, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ⁴koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…
Abstract Number: 2617 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis
Vibeke Strand¹, Namita Tundia², Yan Song³, Dendy Macaulay⁴ and Mahesh Fuldeore⁵, ¹School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Analysis Group, Inc., New York, NY, ⁵AbbVie, Inc, North Chicago, IL
Background/Purpose: Biologic agents are effective in treating patients with rheumatoid arthritis (RA); however, some patients either fail to respond or lose response over time. This…
Abstract Number: 1146 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Christian Gissel¹, Georg Götz², Holger Repp³ and Uwe Lange⁴, ¹Rheumatology, Justus-Liebig-University Giessen, Giessen, Germany, ²Department of Economics and Business, Justus-Liebig-University Giessen, Giessen, Germany, ³Department of Medicine, Justus-Liebig-University Giessen, Giessen, Germany, ⁴Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany
Background/Purpose: In Germany, Rheumatoid Arthritis (RA) can be treated with TNF-α inhibitors after the failure of conventional disease-modifying antirheumatic drugs like Methotrexate. The clinical use…
Abstract Number: 494 • 2014 ACR/ARHP Annual Meeting
Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Chia-Chen Teng², Tao He², Jianwei Leng³, Chao-Chin Lu², Derek Tang⁴, Neel Shah⁵, David J. Harrison⁴ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ⁴Amgen Inc., Thousand Oaks, CA, ⁵1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA
Background/Purpose: An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA)…
Abstract Number: 187 • 2013 ACR/ARHP Annual Meeting
The Health and Economic Consequences Of Delay In Starting Disease-Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Danny Liew, Mark Tacey and Sharon Van Doornum, Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia
Background/Purpose: Several international studies suggest that the time between symptom onset and DMARD initiation in RA patients is longer than is considered optimal. We sought…
Abstract Number: 2366 • 2013 ACR/ARHP Annual Meeting
Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study
Yoshiya Tanaka¹, Yasuhiko Shinmura², Ryo Nakajima², Takahiro Muramatsu², Shuichi Komatsu³, Tadamichi Kubo², Aki Kuroki⁴, Ataru Igarashi⁵, Toshiro Tango⁶ and Tsutomu Takeuchi⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ³Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, ⁴Medical Affairs, AbbVie GK, Tokyo, Japan, ⁵Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ⁶Center for Medical Statistics, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive…
Abstract Number: 1458 • 2013 ACR/ARHP Annual Meeting
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
A Nadkarni, F Lobo and T Juday, Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Several biologic disease-modifying antirheumatic drugs (bDMARDs) are approved for the treatment of moderate-to-severe RA. Switching between bDMARD therapies is common in real-world settings, and…
Abstract Number: 1013 • 2013 ACR/ARHP Annual Meeting
Estimating the Monetary Value of annual Productivity Gained in Early Active RA Patients Receiving Etanercept Plus Methotrexate: Results From the Prize Study
Wei Zhang¹, Nick Bansback², Huiying Sun¹, Ronald Pedersen³, Sameer Kotak⁴ and Aslam H. Anis^1,2, ¹St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Determining the effect of treatment on work productivity of subjects with rheumatoid arthritis (RA) is an important topic given that most sufferers develop the…
Abstract Number: 1836 • 2012 ACR/ARHP Annual Meeting
Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Sharon Van Doornum¹, Lynden Roberts², Mark D. Reed³ and Danny Liew⁴, ¹Department of Medicine (RMH/WH), The University of Melbourne, Melbourne, Australia, ²School of Medicine, James Cook University, Townsville, Australia, ³Rheumatology, Sir Charles Gairdiner Hospital, Nedlands, Australia, ⁴Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia
Background/Purpose: Studies from a number of countries suggest that the time between symptom onset and initiation of DMARD therapy in RA patients is still longer…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].